Clinical trials: Down Syndrome Regression Disorder (DSRD)
Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21)
An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
The goal of this clinical trial is to evaluate whether the monoclonal antibody ublituximab can treat Down Syndrome Regression Disorder (DSRD) by assessing its safety, tolerability, and preliminary efficacy in affected…
- Conditions
- Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21), Neuroinflammatory / Neuropsychiatric Disorder
- Trial name
- NCT07812181
- Testing
- Ublituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonathan Santoro